Allergan said Tuesday it would buy Tobira Therapeutics in a deal worth up to $1.7 billion, to gain access to its experimental therapies for a fatty liver disease called NASH.
Tobira shares skyrocketed more than 600 percent since the deal announcement to more than $36 per share after closing at $4.74 a share on Monday.
Allergan's offer of $28.35 per Tobira share upfront is nearly a whopping 500 percent premium to the stock's close on Monday.
Dublin-based Allergan said Tobira shareholders could get up to $49.84 per share contingent on the company achieving certain milestones.
About 30 percent of people in the United States suffer from fatty liver diseases such as NASH (nonalcoholic steatohepatitis) due to obesity, diabetes and over-indulgent lifestyles, according to the American Liver Foundation.
0 commentaires:
Enregistrer un commentaire